TrialCancer immunology, immunotherapy : CII2022

Efficacy and safety of Wilms' tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial.

Toru Kiguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.